Study details
Enrolling now
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
NCT IDNCT06408194ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 1.6 years
Ages
1–25
Locations
1 site in CA
What this study is about
This trial is testing the safety and how well a new treatment, autologous CD22 CAR T cells, works when given after a commercial CAR T cell therapy called Tisagenlecleucel. The goal is to find out if this new treatment can be safely used in children and young adults with relapsed or refractory B-cell leukemia.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CD22CART infusion
- 2.Take Tisagenlecleucel
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
tisagenlecleucel (CAR T-cell therapy targeting CD19 on leukemia cells)
Drug routes
infusion
Body systems
Oncology